AbCellera Biologics
ABCL
128 hedge funds and large institutions have $371M invested in AbCellera Biologics in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 44 reducing their positions, and 18 closing their positions.
91% more call options, than puts
Call options by funds: $3.46M | Put options by funds: $1.81M
32% more capital invested
Capital invested by funds: $280M → $371M (+$90.5M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
1% less funds holding
Funds holding: 129 → 128 (-1)
6.01% less ownership
Funds ownership: 42.08% → 36.07% (-6%)
16% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.29M |
| 2 |
Two Sigma Advisers
New York
|
+$3.55M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.68M |
| 4 |
Two Sigma Investments
New York
|
+$2.45M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$23.7M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$17.9M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$6.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.07M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.23M |
ABCL Hedge Fund Activity: Q2 2025 in Review
128 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2025, worth a combined $371M — up 32% from $280M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ABCL positions and 18 closed out — a net gain of 1 holder — while 37 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.29M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $23.7M sold.
- 128 institutional investors held AbCellera Biologics (ABCL) as of Q2 2025, down from 129 in Q1 2025.
- Funds reported $371M of AbCellera Biologics stock for Q2 2025, up 32% quarter-over-quarter.
- 19 funds opened new AbCellera Biologics positions in Q2 2025 and 18 closed out, a net change of +1 holder.
- The largest AbCellera Biologics buyer in Q2 2025 was Millennium Management, an estimated $6.29M added.
- The largest AbCellera Biologics seller in Q2 2025 was VOYA Investment Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q2 2025.